At CPHI Europe 2025 in Frankfurt, investors urge European biopharma companies to leverage the continent’s innovation hub status amidst funding challenges. IPO funds have plummeted post-Covid spike, prompting caution among investors. Lack of native funding for Phase II trials leads many European biotechs to seek support abroad.

Singapore’s biopharma capital markets are strong, but focus on manufacturing over clinical assets. Opportunity for collaboration with Europe exists, where technical innovation in assets is strong. EU prioritises boosting domestic drug manufacturing to address shortages. US-EU tariff negotiations aim to encourage local pharmaceutical manufacturing.

To benefit from collaboration with Asia, European biotechs should explore unconventional funding avenues. Venture capital is harder to secure, prompting the need for product-specific financing, creative royalty agreements, and public-private partnerships. Europe’s technical expertise in therapeutic modalities puts it in a unique position for innovation and collaboration.

Read more at Yahoo Finance: time for European biopharma to double down on innovation